ClinicalTrials.gg
CompletedNCT06030973Updated Nov 17, 2026

Opinions of Healthcare Providers About a European Neuromodulation Register

An observational study in Registry, Neuromodulation and Survey, sponsored by Moens Maarten. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Moens Maarten · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
104
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this online survey is to gain further insights in the needs and burden for a European registry for neuromodulation, according to healthcare providers.

02

Conditions studied

  • Registry
  • Neuromodulation
  • Survey
03

In context

Lead sponsor

Moens Maarten is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

In this study male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses) will be eligible to complete the survey. The survey will be spread at the 3ʳᵈ Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg from 31/8/2023 to 2/9/2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses).

Exclusion criteria

Exclusion Criteria:

  • Not involved in management of chronic pain through neuromodulation.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
104 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthcare professionals involved in neuromodulation

    Behavioral: Filling in an online survey

Interventions

  • BehavioralFilling in an online survey

    Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.

06

What researchers measure

Primary outcomes

  1. Healthcare providers their current degree of participation in a registry for neuromodulation.

    Degree of participation in a registry for neuromodulation (question).

    Time frame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.

  2. Healthcare providers their need for a European registry.

    Underlying reasons on why a European registry is needed, or not needed (question).

    Time frame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.

  3. Items that should be included in a registry for neuromodulation, according to healthcare providers.

    Items that should be collection within a registry, evaluated with a multiple choice question.

    Time frame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.

  4. Access regulations to European registry for neuromodulation, according to healthcare providers.

    Access regulations, evaluated with a multiple choice question.

    Time frame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.

07

Study locations

1 site
  • Congres Center
    Hamburg, Germany
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Sep 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2023
First posted
Sep 11, 2023
StartActual
Aug 31, 2023
Primary completionActual
Sep 5, 2023
CompletionActual
Sep 5, 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 17, 2026
Primary completion
Sep 2, 2023→Sep 5, 2023 (actual)
Nov 17, 2026
Study completion
Sep 2, 2023→Sep 5, 2023 (actual)
Nov 17, 2026
Enrollment
100 (estimated)→104 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Completed
    Primary completion Sep 2, 2023→Sep 5, 2023 (now actual)
    Study completion Sep 2, 2023→Sep 5, 2023 (now actual)
    Enrollment 100 (estimated)→104 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06030973
Lead sponsor
Moens Maarten
Responsible party
Moens Maarten (Principal Investigator, Universitair Ziekenhuis Brussel) — Sponsor-investigator
First posted
Sep 11, 2023
Start date
Aug 31, 2023
Primary completion
Sep 5, 2023
Completion
Sep 5, 2023
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion